INTRODUCTION {#sec1-1}
============

According to the World Health Organization (WHO), secondary infertility is defined as a couple\'s inability to bear a child, either due to the failure to conceive or the inability to carry a pregnancy to live birth following either a previous pregnancy or a previous ability to carry a pregnancy to live birth.[@ref1] Despite being poorly studied, secondary infertility rates have been increasing over time and are not negligible compared to primary infertility rates; overall, a male factor is involved in up to 50% of cases.[@ref2]

Several factors are recognized as potential causes of secondary couple\'s infertility.[@ref3] Among them, the potential detrimental contribution of advanced age in terms of male reproductive function remains ambiguous.[@ref4] Although not unequivocal,[@ref5] epidemiological data have suggested that increasing paternal age (more than 35--40 years) is associated with delayed conception,[@ref6] an increased risk of spontaneous pregnancy loss,[@ref7] and a decreased success rate at both intra-uterine insemination[@ref8] and *in vitro* fertilization.[@ref9][@ref10] Likewise, it has been previously shown that semen volume, sperm motility, and sperm morphology decrease with age. In contrast, the relationship between increasing age and sperm concentration remains unclear.[@ref4][@ref11] More specifically, sperm concentration and the percentage of sperm with normal morphology, sperm motility, and ejaculate volume were found to decrease after 40, 43, and 45 years, respectively, whereas total sperm count declines even earlier.[@ref11] A significant role of paternal age has been postulated for a number of genetic factors including numerous severe age-dependent structural chromosomal aberrations, with several X-linked recessive and autosomal dominant disorders have already been clearly confirmed.[@ref4][@ref12]

Besides advanced age, several comorbidities are regarded as possible contributing factors. To this regard, infertile men appear to share a lower general health status regardless of the reasons for infertility.[@ref13][@ref14] More specifically, a deranged metabolism was shown to be actively involved in affecting male reproductive function. In this context, substantial evidence indicates that complex interactions underlie the pathologic relationship between obesity, metabolic syndrome (MetS), and the reproductive axis.[@ref15] Obesity is known to affect fertility in women and is alleged also for men.[@ref2] An excess of adipose tissue is responsible for hormonal imbalance, especially when considering the hypothalamic-pituitary-gonadal (HPG) axis.[@ref16] Nevertheless, the evidence linking obesity to impaired semen parameters is still not univocal despite extensive recent attempts to provide clarity on this controversial topic and its related issues.[@ref17][@ref18][@ref19][@ref20] Similarly, diabetes mellitus (DM) also perturbs both sexual and reproductive hormonal homeostasis and seems to affect spermatogenesis at various levels.[@ref21]

Although MetS was shown to have a detrimental effect on male reproductive health[@ref22][@ref23] in primary infertile men, the impact of MetS on male reproductive function has never been analyzed before in White-European men seeking medical help for secondary infertility. Likewise, the lack of previous clinical evidence and the increasing prevalence of MetS,[@ref24] with its potential impact on both the hormonal milieu and the overall health status of men, prompted us to investigate the role of MetS in male secondary infertility, assessing (i) the prevalence of MetS, (ii) correlations between MetS and clinical characteristics, and (iii) the impact of MetS on semen and hormonal parameters in a cohort of White-European men presenting for secondary couple\'s infertility.

MATERIALS AND METHODS {#sec1-2}
=====================

 {#sec2-1}

### Patients {#sec3-1}

The analyses of this cross-sectional study were based on a sample of 167 consecutive White-European men assessed at a single academic center for secondary couple\'s infertility (noninterracial infertile couples only) between September 2005 and April 2013. Patients were enrolled if they were older than 18 years of age and had either male factor infertility (MFI) or mixed factor infertility (MxFI). MFI was defined after a comprehensive diagnostic evaluation of the female partners. According to the WHO clinical criteria, infertility is defined as not conceiving a pregnancy after at least 12 months of unprotected intercourse regardless of whether or not a pregnancy ultimately occurred.[@ref1] Secondary infertility is defined as the inability to conceive following a previous pregnancy.[@ref1]

Patients were assessed with a thorough self-reported medical history including age and comorbidities. Comorbidities were scored with the Charlson Comorbidity Index (CCI).[@ref25] We used the International Classification of Diseases, 9^th^ Revision. For the specific purpose of the analysis, CCI was categorized as 0, 1, ≥2.

Weight and height were measured for each participant; body mass index (BMI), defined as weight in kg/height in m[@ref2], was assessed for each patient. Testes volume was assessed through a Prader orchidometer. Patients underwent at least two consecutive semen analyses both depicting a condition below the standard values for normal semen parameters according to the WHO criteria.[@ref26]

A venous blood sample was drawn from each patient between 7 a.m. and 11 a.m. after an overnight fast. In all cases, fasting glucose levels were measured via a glucose oxidase method (Aeroset Abbott, Rome, Italy). Total cholesterol, HDL-C, and triglyceride levels were measured with the automated enzymatic colorimetric method (Aeroset Abbott, Rome, Italy). Follicle-stimulating hormone (FSH); luteinizing hormone (LH), prolactin (PRL), thyroid-stimulating hormone (TSH), and 17β-estradiol (E~2~) were measured using a heterogeneous competitive magnetic separation assay (Bayer Immuno 1 System, Bayer Corporation, Tarrytown, NY, USA). Inhibin B (InhB) and anti-Müllerian hormone (AMH) were measured by an enzyme-linked immunosorbent assay (Beckman Coulter AMH Gen II ELISA). Total testosterone (tT) levels were measured via a direct chemiluminescence immunoassay (ADVIA Centaur; Siemens Medical Solutions Diagnostics, Deerfield, IL, USA), and sex hormone-binding globulin (SHBG) levels were measured via a solid-phase chemiluminescent immunometric assay on Immulite 2000 (Medical Systems SpA, Genoa, Italy). Calculated free testosterone (cfT) was derived from the Vermeulen formula. Hypogonadism was defined as tT \<3 ng ml^−1^.[@ref27] Calculated free testosterone (cfT) was derived from the Vermeulen formula.[@ref28] The same laboratory was used for all patients.

MetS was defined according to the 2004 updated National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (ATP III) criteria (at least 3 of the following criteria: waist circumference \>102 cm; triglycerides equal to or \>150 mg dl^−1^ (1.7 mmol l^−1^); HDL \<40 mg dl^−1^ (1.03 mmol l^−1^); blood pressure equal to or \>130/85 mmHg or use of medication for hypertension; and fasting glucose equal to or \>100 mg dl^−1^ (5.6 mmol l^−1^) or use of medication for hyperglycemia).[@ref29]

Data collection followed the principles outlined in the Declaration of Helsinki; all patients signed an informed consent agreeing to supply their own anonymous information for future studies. The study was approved by our Local Ethical Committee.

### Statistical analyses {#sec3-2}

Data abstraction was performed by six different abstractors on 100% of the medical records at the time of office admission. The data quality analysis showed an error rate of 0.3%.

Data are presented as means (medians; ranges). The statistical significance of differences in means and proportions was tested with the one-way analysis of variance and Pearson Chi-square test, respectively; 95% confidence intervals (95% CIs) were estimated for the association of categorical parameters. Exploratory analyses were initially applied to all variables; variables were retained when clinically significant to the results. Univariable (UVA) and multivariable (MVA) logistic regression models tested associations between the clinical predictors and pathologic semen parameters. Odds ratios and their 95% CIs were estimated.

Statistical tests were performed using SPSS version 19 (IBM Corp., Armonk, NY, USA). All tests were two-sided, with a significance level set at 0.05.

RESULTS {#sec1-3}
=======

**[Table 1](#T1){ref-type="table"}** lists the characteristics and the descriptive statistics of our secondary infertile patients. Overall, MFI and MxFI were found in 138 patients (82.6%) and 29 patients (17.4%), respectively. MetS was found in 20 (12%) secondary infertile patients. The analysis of our data allowed us to highlight several features capable of segregating patients diagnosed with MetS (+MetS) from their non-MetS counterpart (−MetS). From the descriptive standpoint, +MetS patients were older and with a higher BMI (all *P* \< 0.001). Further differences were observed in terms of hormonal profile (lower InhB, AMH, tT, and SHBG circulating levels in men with MetS; all *P* ≤ 0.03); consistent with these findings, hypogonadism was more common in the +MetS group (*P* = 0.01). When considering seminal parameters, lower semen volume, sperm concentration, and rates of normal morphology (all *P* ≤ 0.03) were observed in patients with MetS.

###### 

Characteristics and descriptive statistics of the entire cohort of patients according to positivity NCEP/ATP III criteria for MetS

![](AJA-19-368-g001)

**[Table 2](#T2){ref-type="table"}** details logistic regression models testing the associations between clinical predictors and pathologic sperm parameters. At univariable analysis, higher FSH, lower InhB levels, and lower mean right testis volume were associated with pathologic sperm concentrations (all *P* ≤ 0.04). Conversely, age, CCI, and +MetS were not. Similarly, higher FSH levels were univariably associated with pathologic progressive motility (*P* = 0.002). No variable was associated with pathologic sperm morphology. At MVA, no variable reached statistical significance for any pathological sperm condition.

###### 

Logistic regression models predicting pathologic sperm parameters according to WHO 2010 criteria OR (95% CI) in the whole cohort of patients

![](AJA-19-368-g002)

DISCUSSION {#sec1-4}
==========

We cross-sectionally tested the rate of MetS in a relatively large sample of White-European men seeking first medical attention for secondary couple\'s infertility at a single academic outpatient center. Likewise, we assessed the impact of MetS on clinical and semen characteristics in the same sample. Our interest was fuelled by (i) epidemiologic data suggesting an increasing prevalence of secondary infertility;[@ref1][@ref30] (ii) previous data showing the increasing prevalence of MetS among European men;[@ref24] (iii) the potential impact of MetS on the overall hormonal milieu,[@ref15][@ref31] and male\'s overall health status;[@ref32] and (iv) the lack of published observations of an association between MetS and male secondary infertility.

To the best of our knowledge, these findings offer the first demonstration that more than one out of eight men presenting for secondary couple\'s infertility meets NCEP-ATP III criteria for MetS. This prevalence is higher than that observed in the general population of the same age range.[@ref33]

We chose NCEP-ATP III criteria to define MetS because they are the most widely used and readily available to physicians, thus facilitating their clinical and epidemiological use. Moreover, this definition does not harbor any preconceived notion of the underlying cause of MetS, whether it be insulin resistance or obesity. By adopting stringent enrolment criteria we were able to select a homogeneous White-European male sample (including only noninterracial infertile couples), thus minimizing the impact of potential unpredictable genetic biases.

The current findings demonstrate that +MetS patients were older and had a higher prevalence of hypogonadism compared to their −MetS counterpart. When assessing patients' comorbidity burden by means of the CCI scoring system, we found no significant general health status decline in men with MetS. Conversely, we have previously reported that primary infertile men with MetS are generally less healthy than their −MetS counterparts;[@ref34] to this regard, we may speculatively argue that this difference is not observed in secondary infertile men due to their higher age and their consequent higher age-related comorbidity load. Moreover, the CCI was originally designed to assess comorbidities typically associated with 1-year mortality; therefore, it includes medical conditions that are more frequently found in an older or even elderly population and usually not in a younger population (such as infertile men). Thus, by definition and by its inherent limits, CCI completely excludes any item related to blood hypertension or sexually transmitted diseases which, in contrast, may be relevant medical conditions in young infertile men in the real-life setting.[@ref14][@ref35]

The second aspect of major clinical importance for these findings is related to patient age. We report the novel finding of a significant age increase among secondary infertile men with MetS compared with other infertile patients, thus confirming our own previous findings in primary infertile men.[@ref34] Stone *et al*.[@ref11] recently observed that the 34--40 years age range appears to be indicative for the first manifestations of age-related effects on seminal parameters. In this context, the likelihood of pregnancy following intercourse declines continuously in men older than 34 years of age, regardless of the female partner\'s age.[@ref11] Sperm concentration and the percentage of sperm with normal morphology, sperm motility, and ejaculate volume were found to decrease after 40, 43, and 45 years, respectively, whereas total sperm count declines even earlier.[@ref11] Increasing paternal age (above the age of 35--40 years) was found to be associated with delayed conception in a large cohort of British fertile couples,[@ref6] with an increased risk of spontaneous pregnancy loss,[@ref7] and a decreased success rate for couples undergoing assisted reproductive techniques,[@ref8][@ref9][@ref10] although these findings were not always unanimously confirmed.[@ref5] Considering the mean age of our secondary infertile patients, along with previous evidence indicating a drift over delayed fatherhood[@ref12] and the possible detrimental consequences of this, +MetS infertile patients are at an even higher risk, as the current findings outlined that they are older than infertile not meeting the criteria for MetS.

Our analyses confirmed the association between MetS and male hypogonadism in the general population[@ref36] and in infertile patients.[@ref19][@ref20] We found that tT was reduced in +MetS patients compared to the --MetS group whereas cfT did not seem to be affected by this condition. In contrast, Lotti *et al*.[@ref22] reported decreased values of both tT and fT, while Leisegang *et al*.[@ref23] only reported an fT reduction in this specific setting. Along with tT, SHBG was also found to be reduced in our subset of +MetS patients. Although obesity and MetS are known to lower SHBG levels,[@ref37] the actual impact on fT is still under debate. In this context, the results of the Massachusetts Male Aging Study showed no difference in terms of fT in overweight men.[@ref38] Conversely, MacDonald *et al*.[@ref39] reported the results of a meta-analysis showing a negative relationship for tT, SHBG, and fT with increased BMI values. Contextual decreases in both SHBG and tT may partially account for unmodified fT levels in our patients. This is important to note, as the patients in the current study were considerably younger than those reported in the studies just cited, thus potentially disguising any age-related effect on T levels.[@ref40] As a whole, obesity-related and MetS-related hypogonadism is known to be accompanied by a plethora of factors simultaneously acting centrally and peripherally.[@ref15] However, the impact of MetS on endocrine testicular function does not appear to be restricted only to T homeostasis. We observed that InhB and AMH levels were both reduced in +MetS patients as reported in previous studies.[@ref34][@ref41]

Our findings show the potential role of MetS in affecting semen parameters in secondary infertile men. More specifically, semen volume, sperm concentration and normal morphology were reduced in the +MetS subcohort, with a lower, yet not significant, prevalence of oligospermic, asthenospermic, and teratospermic patients. To this regard, the relationship between MetS and seminal parameters remains controversial. Indeed, two observational studies[@ref22][@ref23] have shown an association between MetS and poor sperm parameters in men broadly presenting for couple infertility. Conversely, our previous findings regarding primary infertile men reported no noticeable detrimental effect induced by MetS.[@ref34] We may speculate that several factors might account for these differences. Emphasis on obesity when defining MetS (such as the case of Lotti *et al*.[@ref22] using the International Diabetes Federation worldwide definition) and older age (as observed in our secondary infertile patients) might unveil the impact of MetS on seminal parameters whereas younger age and NCEP-ATP III definition, as observed in our sample of primary infertile men, would not.[@ref34]

A recent study reported that 45 oligo-terato-asthenospermic MetS patients treated with metformin for six consecutive months experienced improvements in hormonal, metabolic and, above all, semen characteristics.[@ref42] Such evidence suggests that in selected patients, improvement of the metabolic component might positively impact male reproductive health.

Our study is not devoid of limitations. First, this was a hospital-based study, raising the possibility of a number of selection biases. The sample was recruited from a single academic outpatient clinic, and despite the fact that it was made up of probably the largest, to date, homogeneous group of White-European secondary infertile men (restricted to noninterracial infertile couples), several larger studies across different centers and populations will be needed to substantiate our findings. Second, the analyses were implemented in a cross-sectional setting that lacked a comparison with a same-race, age-matched sample of fertile individuals. Third, although one of the strengths of these analyses was the availability of a rather comprehensive and consistent hormonal milieu for each patient, we lacked data regarding potential molecular alterations in spermatogenesis, which might be of importance in investigating the eventual impact of MetS on semen health. Fourth, the observational nature of the study prevents any kind of causal interpretation between MetS and male infertility.

Overall, MetS emerged as a powerful modifier not only of the endocrine milieu but also of semen quality in the current sample of patients. Molecular alterations in spermatogenesis, assessed for instance through DNA sperm fragmentation analysis, will perhaps provide more detailed information.
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